CN1988888A - Encapsulated transfer factor compositions and methods of use - Google Patents
Encapsulated transfer factor compositions and methods of use Download PDFInfo
- Publication number
- CN1988888A CN1988888A CN 200580022833 CN200580022833A CN1988888A CN 1988888 A CN1988888 A CN 1988888A CN 200580022833 CN200580022833 CN 200580022833 CN 200580022833 A CN200580022833 A CN 200580022833A CN 1988888 A CN1988888 A CN 1988888A
- Authority
- CN
- China
- Prior art keywords
- transfer factor
- preparation
- glucosan
- described method
- compositions
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Abstract
Compositions comprising transfer factor and/or glucan, such as hybrid glucan, coated with a hydrophobic or lipid coating. The composition can be combined with nutraceuticals including zinc, essential fatty acids, lactic acid generating bacteria, etc. Also provided are methods for prevention and treatment of animal pathologies using these compositions as well as methods for making them.
Description
Invention field
The present invention relates to the compositions of encapsulation, comprising: (1) is with the transfer factor of hydrophobicity or lipid coating bag quilt and/or (2) glucosan with hydrophobicity or lipid coating bag quilt, such as fungus glucosan or hybridization glucosan.This based composition can be used for prevention and treatment pathologic situation.
Background of invention
The transfer factor that is produced by leukocyte and lymphocyte is to have about 44 amino acid whose little water soluble polypeptide classes, their stimulate or the immunity of transitional cell mediation from body one by one to another and cross over species, but do not produce anaphylaxis.Because transfer factor less than antibody, so they can not shift antibody-mediated reaction, can not induce antibody to produce yet.The method of the characteristic of transfer factor, feature and acquisition transfer factor is described in U.S. Pat 4,816, in 563, US5,080,895, US5,840,700, US5,883,224 and US6,468,534, the content of these documents is introduced the application as a reference.
Transfer factor has been described as effective therapeutic agent (Viza etc.) of herpes simplex virus; To the treatment (U.S. Pat 4,435,384) of acne stain with as to the oidiomycetic treatment means of white (Khan etc.).Transfer factor also is used for the treatment of with the intestinal cryptosporidiosis (McMeeking etc.) among the receiver of specific transfer factor treatment.Still etc. also confirm by using from suffering from chickenpox, or in other words prevent chickenpox to infect to the transfer factor pretreat child of the individuality of vzv antigen sensitization.The antigenic specificity transfer factor be that fullest obtains studying and verified they carry the antigen recognition ability that experience donor can for the receiver of first Application.Can be estimated as the individuality in transfer factor source or the animal antigen sensibilization to being paid close attention to.Herein term antigen is defined as and causes cell-mediated immunoreactive arbitrary substance.Yet, contain from the acquired immunity of all colonies and adopting property of the whole body transfer of a para-immunity be provided thus as the transfer factor of in the commercial cattle colostrum extract that derives from fauna (for example cattle), finding.But one or more transfer factors can be available from the dialysis extract of dissolved cell or available from the extracellular fluid extract that contains transfer factor.The common source of transfer factor is colostrum and ovum.Common practice is to be that the preparation that contains transfer factor is called active component (being transfer factor or TF).The transfer factor extract that contains transfer factor is also referred to as transfer factor in this article.To be defined as the defat water-soluble substances that passes through nominal 10,000 molecular weight filter membranes from the transfer factor of cattle colostrums extract from colostrum.Prepared various organisms have been comprised that infectious bovine rhinotracheitis virus has active milk-derived transfer factor just.One of specific effect of transfer factor is NK cell (NK) cytoactive that significantly increases.Natural killer cell provides the ingredient of the defense function of antagonism virus as the innate immunity system of defense.
Although transfer factor is a polypeptide, it is shockingly stable in gastrointestinal tract according to reports.For example, Kirkpatrick has compared the oral and parenterai administration of transfer factor in clinical research.Kirkpatrick，Biotherapy，9：13-16，1996。His conclusion is that the result has refuted any argument that gastrointestinal acidity or enzyme environment may hinder the oral therapy of using transfer factor.
When attempting TF checked order, the terminal tolerance order of the N-of transfer factor peptide edman degradation according to reports.Kirkpatrick，Molecular Medicine，6(4)：332-341(2000)。
Transfer factor also has been successfully used to treat the compositions that Animal diseases and syndrome comprise ruminant.Referring to laid-open U.S. Patents publication number on the 24th US2003/0077254 April in 2003.
Therefore, think that transfer factor is stable in gastrointestinal tract and cud.
Summary of the invention
The present invention is based on transfer factor is not to stablize this discovery as once thinking.This is true especially in the situation of ruminant.
The invention provides compositions, wherein transfer factor and/or glucosan are " encapsulation ".Encapsulation protection transfer factor and/or glucosan avoid inactivation in gastrointestinal tract.This class encapsulation is even more important to finding to be digested in cud in the ruminant for problem.Verified when to the transfer factor encapsulation and to the ruminant administration, bioavailability is improved.In preferred embodiments, transfer factor and/or glucosan encapsulation formed coating by mixing around transfer factor and/or glucosan with lyophobic dust or lipid.
Can encapsulation preparation and mineral, antioxidant, aminoacid and the combination of other dietetic product of the glucosan of the transfer factor of encapsulation and/or encapsulation will be contained." encapsulation preparation " used herein refers to the transfer factor preparation of encapsulation and/or the glucosan preparation of encapsulation.Therefore, the preparation of encapsulation can refer to encapsulation transfer factor preparation, encapsulation the glucosan preparation or not only contained the transfer factor of encapsulation but also contained the encapsulation preparation of the glucosan of encapsulation.
One aspect of the present invention is for prevention animal to be given the preparation of encapsulation.
Another aspect is to give the preparation of encapsulation so that treat the pathologic situation, such as heart disease, inflammation and angiopathy to animal.
Another aspect is to give the preparation of encapsulation so that increase food conversion to animal.
Another aspect is to provide the transfer factor preparation, such as the preparation of the encapsulation of the transfer factor that comprises one or more targeting.
Another aspect of the present invention is to provide the transfer factor preparation, and wherein transfer factor comprises the transfer factor of targeting, and for example, its targeting is to herpes simplex virus 1, herpes simplex virus 2, helicobacter pylori, Champhobactor or chlamydia.
Another aspect of the present invention is to provide the preparation of the encapsulation that also comprises lactobacillus.
Another aspect of the present invention is to provide the preparation of the encapsulation that also comprises phytic acid, Olive leaf P.E, Aloe extract powder and cupreol.
Another aspect of the present invention is to provide the preparation of the encapsulation that also comprises yeast extract.
Another aspect of the present invention is to provide the preparation of the encapsulation that also comprises ascorbic acid.
Another aspect of the present invention is to provide the preparation of the encapsulation that also comprises dipotassium hydrogen phosphate.
Another aspect of the present invention is to provide the preparation of the encapsulation that also comprises potassium chloride, magnesium sulfate and calcium pantothenate.
Another aspect of the present invention is to provide the preparation of the encapsulation that also comprises vitamin E.
Another aspect of the present invention is to provide the preparation of the encapsulation that also comprises vitamin C, vitamin A, vitamin D3, vitamin B1, vitamin B2 and vitamin B12.
Another aspect of the present invention is to provide and also comprises for example preparation of the encapsulation of protein-zinc of zinc.
Another aspect of the present invention is to provide the transfer factor preparation, wherein by described formulation example is realized the cud shunting as inject animal by intravenous, intramuscular or subcutaneous injection.
Another aspect of the present invention is to provide the transfer factor preparation, wherein by with in the said preparation transvaginal, intranasal, internal rectum be administered to animal, be applied directly on the mucosa or esophageal groove is open realizes the cud shunting by inducing.
Another aspect of the present invention is to provide the method for the preparation for preparing encapsulation as herein described, is undertaken by various components are merged into described preparation.
Another aspect is to provide and prepares the method for hybridizing glucan, is undertaken by two kinds of different funguses are contacted in culture such as this based composition of snake venom that makes the fungal cell wall degraded.This allows to carry out the heredity exchange between two kinds of funguses, described two kinds of funguses provide the hybridization fungus goods of preparation hybridization glucan and other cross combination thing.
Also disclosed by the hybridization fungus of this method preparation and hybridization glucan and other hybrid molecules of in this class hybridization fungus, finding.
The accompanying drawing summary
Accompanying drawing 1 has been listed the result that the transfer factor preparation of the encapsulation of use table 7 obtains.In the time will comparing with the matched group that does not use the transfer factor treatment with the animal of the transfer factor of encapsulation treatment, sickness rate reduces to 3.1% from 15.5%, and mortality rate reduces to 0% from 5.5%.In addition, weight increase every day of matched group is 1.85lbs/ days, by comparison, uses weight increase every day of those animals of the transfer factor preparation for treating of encapsulation to be 3.05lbs/ days.
Accompanying drawing 2 for the transfer factor preparation of the encapsulation that relates to table 7 in second research using high application in stress the different field studys of cattle.In this research, compare with the matched group of not accepting transfer factor, use in the animal of transfer factor preparation for treating of encapsulations at those, the animal sickness rate reduces to 2.6% from 83%, and mortality rate reduces to 0% from 24%.In addition, matched group colony has 0.9lbs/ days weight increase, and by comparison, those use the weight increase of animal of the transfer factor preparation for treating of encapsulation to be 3.1lbs/ days.
Detailed Description Of The Invention
The preparation of packing of the present invention contains the transfer factor of packing and/or the glucan of packing, comprises the hybridization glucan. Can be with transfer factor and/or glucan packing or as the mixture packing respectively separately. Perhaps, can be to whole preparation packing.
The present invention can use various forms of transfer factor. They comprise from cell such as the lymphocyte, leucocyte and the ovum that contain transfer factor discharge and from extracellular fluid such as the secretion transfer factor of gathering colostrum and the blood. Another kind of form is included in the cell or the transfer factor of the pre-secretion of finding on the cell surface. Can also use the transfer factor that derives from leucocyte, colostrum or ovum and have the substantially purifying of the specific activity that is lower than 10,000 Dalton molecular weights and has at least 5000 units/absorbance unit in 214 nanometers. The transfer factor of using in the embodiment of the invention and relating in following table and further relate in the remainder of describing in detail is extracted colostrum and the ovum of gathering in the overall storehouse of the milk cow of lactation. Will be at embodiment, table and hereinafter describe in the transfer factor used be further defined as the degreasing water-soluble substances that passes through nominal 10,000 molecular weight filter membranes from colostrum. Although the transfer factor that colostrum is derived is used for researching and developing preparation of the present invention, any person skilled in the art can use other transfer factor kind and source as everyone knows.
The optional source of transfer factor includes but not limited to transfer factor, the ovum transfer factor of birds and the transfer factor of separating the colostrum of gathering in non--Niu animal such as goat, pig, horse and people. In addition, can use the transfer factor from any amount source to make up in the preparation of the present invention. Transfer factor can also derive to expressing one or more transfer factor or passing through the recombinant cell that leukocytic clone expands genetic modification.
The optional kind of transfer factor includes but not limited to the transfer factor of target. The target transfer factor comprises the transfer factor in the source that gathering controls oneself is exposed to following material: (1) one or more viruses, or other infectious organisms; (2) one or more produce immunoreactive antigen; Or the combination of (3) organism and antigen. The example of this viroid or other infectious organisms comprises herpes simplex virus 1, herpes simplex virus 2, helicobacter pylori, Champhobactor and Chlamydia, bovine rhinotracheitis virus, parainfluenza, respiratory syncytial virus vaccine, (modified) live virus of attenuation, campylobacter fetus, leptospira canicola, grippotyphosa, hardjo, Leterohaemorrhagiae, pomona bacterin, bovine rota-coronavirus, the Escherichia coli vaccine, the Shore clostridium, septicum, the hemolytic acinetobacter calcoaceticus, Novy, Sordellii, Bacillus perfringens C﹠D type, vaccine, toxoid, Haemophilus somnus, the haemolysis pasteurella, the Multocida vaccine. Yet those skilled in the art are easy to recognize that multiple other virus and other infectious organisms can be applied to the present invention. Example comprises listed those among appendix I and the appendix II.
Enumerated the typical composition of montmorillonite in the table 1.
Enumerated the transfer factor preparation that is used for the treatment of various animals and pathologic condition among the table 2-6. In each case, packing transfer factor not as described herein. But, be easy to use hydrophobicity or these preparations of lipid-coated packing transfer factor in separately, after this mix with other composition in the preparation.
Table 2 has represented to be used for the treatment of the decomposition of the preparation of the transfer factor dietetic product of Cushing syndrome, Cushing disease, adenoma, onchocercosis, hypothyroidism or EPM and carrier. " lb " (pound) that relates in table 2 and all other tables refers to the poundage of body weight.
In the 2nd, 3 and 4 hurdles of table 2-6 display respectively with the high and low and preferred amounts roughly that remains to be given with single dose the preparation composition of animal of amount/batheroom scale. Preparation in the table 3 and 4 is very similar to the preparation in the table 2, but they are specifically designed to respectively dog and cat. The preparation of expression mainly designs for domestic animal in the table 2. Design 5 ounces of prescriptions listing in the 5th hurdle and be the animal in order to give 1000 pounds, but can change and can give in some cases 500 pounds of animals. The average weight of horse is about 1000 pounds. 28.3gm dosage in the table 3 is to calculate for the dog that body weight is about the 100-200 pound, but also this dosage can be given 15 pounds dog. 2.2gm prescription in the table 4 is used for body weight and is about 15 pounds cat. But because these preparations are made up of dietetic product and transfer factor, so those skilled in the art will recognize that this scope and non-deterministic and not as allopathic medicine scope like that crucial.
In addition, the preparation among the design table 2-4 mainly is in order to treat chronic disease, and the preparation in the design table 5 mainly is for acute disease, and the preparation in the table 6 both had been used for acute disease, is used for again chronic disease. All preparations can be given with heavy dose and be realized acute reaction.
Table 7 provides the transfer factor preparation of the packing that is used for the treatment of pathologic condition. This transfer factor preparation comprises the transfer factor that derives from ox and birds source and/or one or more hybridization glucans of packing at least. Glucan part in the preferred said preparation also is packing. Other composition comprises birds transfer factor, cupreol, phytic acid (IP6), Olive leaf P.E, aloe extract powder, probio, bacillus subtilis, bifidobacterium longum, bacillus alcalophilus, lactobacillus acidophilus, enterococcus faecalis and the Saccharomyces cerevisiae of zinc albuminate, target. In preferred embodiments, comprise all mentioned components in this transfer factor preparation.
In preferred packing embodiment, the amount of transfer factor in preparation is 10mg-12gm/oz, more preferably 100mg-6gm/oz, and 10mg-3gm/oz most preferably.
Use is preferably the 25%-150wt/% of transfer factor, and the hydrophobicity of about 50-150wt/% and about 75-125wt/% or lipid-coated are given the transfer factor packing, wherein most preferably wait weight.
In preferred embodiments, being used for hybridization glucan of the present invention is present in Cordyceps and particularly Cordyceps sinensis hybrid strain or derives from these hybrid strains. Induce a kind of technology of Cordyceps hybridization to comprise two kinds of different strains or kind plating on the single agar plate with the crotalin inoculation, as describing in detail in embodiment 17 and 18. As described, snake venom works to weaken the cell membrane of Cordyceps bacterial strain/kind, this so that they grow each other near the time between bacterial strain/kind, carry out the caryoplasm exchange. In preferred embodiments, the hybrid strain that glucan is hybridized in generation the present invention is available from Pacific Myco Products, Santa Cruz, the Cordyceps sinensis Alohaensis of California.
There are many different Cordyceps strains, and think that because its variable asexual mycelial growth form causes many systematists they are variety classes. The non-exclusive list of bacterial strain comprises: Paecilomyces hepiali Chen, Cephalsporim sinensis, Paecilomyces sinensis Cn80-2, Scydalilum sp., Hirstutella sinenis, Mortierella hepiali, Chen Lu, Topycladium sinensis, Scytalidium hepiali, G.L.Li. The preferred embodiment of the invention has been utilized from one or more the hybridization glucan of crossbred in these different strains, yet the present invention can preferentially comprise the glucan from non--hybrid strain alternatively. Alternative embodiment has been used full hybridization Cordyceps, for example Cordyceps sinensis Alohaensis. The hybridization glucan also comprises those hybridization glucans by the acquisitions such as source such as oat of hybridization feed.
When using glucan or hybridization glucan, preparation preferably contains the complete organism/oz of 10mg-18gm, the more preferably complete organism/oz of 100mg-10gm and the most preferably complete organism/oz of 100mg-5gm.
Can also use the purifying of equivalent or partially purified glucan or hybridization glucan and associated ucleosides (for example cordycepin (3 ' desoxyadenossine), adenosine and N6-(2 ethoxy)-adenosine).
With regard to the transfer factor of packing, the amount of preferred hydrophobicity or lipid-coated is about the 25%-150wt/% of hybridizing glucan, about 50-150wt% or about 75-125wt/%, wherein equal weight most preferably.
Other composition in all right packing preparation. For example, can distinguish packing IP6, cupreol, Olive leaf P.E, aloe extract and/or vitamin C and maybe they and one or more compositions can be merged, after this carry out packing. In preferred embodiments, the amount of IP6 is 10mg-3gm/oz, or a kind of preferred situation is 100mg-2gm/oz, and 100mg-1gm/oz most preferably. The preferred amounts of cupreol is 10mg-3gm/oz, or preferred 100mg-2gm/oz,, and 100mg-1gm/oz most preferably. The preferred amount of Olive leaf P.E is 2mg-2gm/oz, more preferably 5mg-1gm/oz, and 5mg-500gm/oz most preferably. The preferred amount of aloe extract is 2mg-1000mg, more preferably 5-500mg/oz, and 5-250mg/oz most preferably. Ascorbic amount can be 10mg/oz-10gm/oz, or preferred 100mg-8gm/oz, and 100mg-5 gm/oz most preferably.
The amount of the transfer factor of using in the preparation and/or the amount of glucan or the preparation that gives changes according to the order of severity of the clinical manifestation that presents. In addition, compare with recipient's kind, the kind that the amount of the transfer factor that the recipient is given is originated with transfer factor changes. Observed and ox has been derived from the transfer factor of ox kind recently the transfer factor from another kind such as birds is more effective. Therefore, when the source of transfer factor and recipient are variety classes, preferably increase the amount of transfer factor.
Expectation gives the transfer factor of packing and the preparation of zinc and at least a essential fatty acid can produce at least part of effective treatment to CS, Cushing disease, adenoma and other benign tumour, onchocercosis, hypothyroidism or EPM. During listed other dietetic product, this treatment is more effective in adding table 2. Except as otherwise noted, dosage is by milligram/pound. Be present in the amount of the composition in 5 ounces of transfer factor preparations that contain other preferred dietetic product as shown in table 2 the 5th hurdle.
The transfer factor of the packing of the about 0.75mg/lb transfer factor of dosage that the animal that suffers from CS, Cushing disease, adenoma or other benign tumour, onchocercosis, hypothyroidism or horse protozoan myelitis (myelytis) is given is once a day united about 0.49mg/lb zinc and essential fatty acid (namely 3,6,9 omega-3 fatty acids) 20.57mg/lb Semen Brassicae Campestris oil, safflower oil or the linseed oil in source should be so that the symptom of carcinoid size and/or these listed diseases reduce about 30%-50%. Certainly, all these compositions should be pharmaceutically acceptable to the animal of accepting them.
The combination of the vitamin C of about 2.16mg/lb and the yeast of 2.29mg/lb and above-mentioned transfer factor and other fatty acid nutritive goods should be so that the symptom of carcinoid size and/or above-mentioned disease reduces about 40%-50%.
In all preparations of the present invention, preferably make the salinization of metal dietetic product albumen because these forms for animal be easier to digestion and because of the protein salt form more stable to pH.Nutritional labeling among the table 2-7 in the preparation is for being used for the treatment of various described diseases and syndromic active component.Comprise that filler and carrier are to make preparation more agreeable to the taste and help to preserve mixture for animal.They comprise silicon dioxide, maltodextrin, Semen sojae atricolor and Semen arachidis hypogaeae powder, Oleum Arachidis hypogaeae semen, glucose, milk surum, spice and correctives.Blended tocopherols and choline chloride are dietetic product, but still can obtain effective effect as herein described by these two kinds of compositions of deletion from preparation.
Not the transfer factor of encapsulation ruminant for example the previous application in the cattle produced significant beneficial effect.For example, referring to laid-open U.S. Patents publication number on the 24th US2003/0077254 April in 2003, the document intactly is incorporated herein by reference.Find the oral administration of transfer factor in stress cows and unstable subsequently.Finding that transfer factor is having in the presence of rumen fluid and the flora behind external inactivation, determining that the success of previous use transfer factor in ruminant is because of existing due to the esophageal groove.When non-stress the time, esophageal groove provides the part shunting of cud.But, in stress colony, esophageal groove be closed and the transfer factor preparation is divided and flows into cud.Discovery forms the preparation of encapsulation even also be enough to provide the essence shunting of cud (for example 85%) in stress colony with lyophobic dust or the transfer factor of lipid encapsulation and/or glucan.
Become known for various other methods of cud shunting.In one embodiment, with encapsulation or the preparation direct injection of encapsulation (subcutaneous, intramuscular or intravenous) not, thereby not only walk around cud but also walk around whole digestive system.Similarly, intravaginal, internal rectum or other are administered directly to mucosa, under the eye conjunctiva, walk around digestive system and particularly cud.Perhaps, can be with preparation and the various solvent that can allow direct cutaneous to absorb.In addition, the method that the various ruminant esophageal grooves of stimulation known in the art are open, and the preparation that this class opening can make oral administration is immediately by reaching gastrointestinal tract, thus walk around cud.
In particularly preferred embodiments, help the cud shunting by the transfer factor preparation that uses encapsulation.
Can produce the transfer factor of encapsulation and/or the glucosan preparation of encapsulation according to variety of way.In preferred embodiments, as U.S. Pat 5,190,775, US6,013,286 and US application 2003/0129295 described in transfer factor in the encapsulation preparation and/or each of glucosan, above-mentioned document full content separately is incorporated herein by reference.Briefly; method described in the patent of citation and the application concentrates on uses hydrophobicity or the lipid coating that the degraded character of protective effect to avoid cud is provided; unite the buoyant additional surfactants coating of the preparation that suppresses encapsulation, leave cud and further pass through digestive system so that help preparation.The preferred embodiment of hydrophobic coatings includes but not limited to vegetable oil and hydrogenated vegetable oil, and they derive from Petiolus Trachycarpi, palm kernel, cotton seed, Semen sojae atricolor, corn, Semen arachidis hypogaeae, Ba Basu, Helianthi or safflower oil and composition thereof separately or are made by them.In addition, this class coating can be mixed with wax, such as, but be not limited to Cera Flava, pertroleum wax, rice bran wax, castor wax, microwax and composition thereof.The preferred embodiment of surfactant includes but not limited to the lactoyl esters of gallic acid of polysorbate60, polysorbate80, propylene glycol, dioctylis sulfosuccinas natricus, sodium lauryl sulphate, fatty acid, polyglycereol esters of fatty acid and composition thereof.
The preparation of this class encapsulation also has multiple benefit except that its effect in the cud shunting.At first, encapsulation prevents the preparation degraded and the obviously long shelf life is provided.The preparation of this class encapsulation can tolerate the temperature that is heated above 135 , and this temperature is to granulate or process in the production method of human consumable goods necessary many comprising to animal feed.Encapsulation has also been removed bitterness and the abnormal smells from the patient that is present in usually in the preparation, and has greatly increased palatability thus.Encapsulation has also been given pliability in preparation, make fragile composition can not interact with coarse mineral, salt or variable pH.
Because shelf life, heat stability, palatability and pliability increase,, the transfer factor preparation of the preparation of encapsulation such as encapsulation consumes so being preferred for the human and animal.Be used for the transfer factor preparation that the human preferred embodiment that consumes includes but not limited to introduce at processed food such as frumentum, dessert, potato chips or piece strip food encapsulation.The preferred embodiment that is used for animals consuming includes but not limited to sneak into feed granules, lick salt, lick the transfer factor preparation of the encapsulation of molasses or other processing feed product.
The transfer factor preparation of encapsulation is applied to increase efficiency of food conversion.Efficiency of food conversion is the ratio that organism can become food conversion body weight, and also is called feed efficiency in cattle industry.The transfer factor preparation of encapsulation has been successfully used to increase with the speed that increases than untreated cattle the body weight of cattle, even also is like this in the ill situation of the cattle of treatment.Therefore, the preparation of encapsulation is not limited to prevention and treatment pathologic condition, and is applied to the others of organism general health and growth.
The transfer factor preparation of encapsulation of the present invention comprises the pharmaceutical composition that is suitable for administration.In preferred embodiments, pharmaceutical composition is a water-soluble form, and such as existing as pharmaceutically acceptable salt, its implication is to comprise the bronsted lowry acids and bases bronsted lowry addition salts." pharmaceutically acceptable acid-addition salts " refers to the biological effectiveness of those maintenance free alkalis and is not biology or the undesirable salt of others, itself and mineral acid and organic acid form, the all example hydrochloric acids of described mineral acid, hydrobromic acid, sulphuric acid, nitric acid, phosphoric acid etc., and organic acid such as acetic acid, propanoic acid, glycolic, acetone acid, oxalic acid, maleic acid, malonic acid, succinic acid, fumaric acid, tartaric acid, citric acid, benzoic acid, cinnamic acid, mandelic acid, methanesulfonic acid, ethyl sulfonic acid, right-toluenesulfonic acid, salicylic acid etc." pharmaceutically acceptable base addition salts " comprises that those derive from the salt of inorganic base, such as sodium, potassium, lithium, ammonium, calcium, magnesium, ferrum, zinc, copper, manganese, aluminum salt etc.Preferred especially ammonium, potassium, sodium, calcium and magnesium salt.The salt that derives from pharmaceutically acceptable organic avirulence alkali comprises the salt of following chemical compound: the primary, the second month in a season and tertiary amines, the amine that replaces, the amine that comprises naturally occurring replacement, the cyclammonium class, with the basic ion exchanger resin, such as 2-aminopropane., trimethylamine, diethylamine, triethylamine, tripropyl amine (TPA) and ethanolamine.
Pharmaceutical composition can also comprise one or more following compositions: carrier protein, such as serum albumin; Buffer agent is such as sodium acetate; Filler is such as microcrystalline Cellulose, lactose, corn and other starch; Binding agent; Sweetener and other correctives; Coloring agent; And Polyethylene Glycol.Additive is well-known in the art and is used for various preparations.
In another embodiment, pharmaceutical composition is joined in the micellar preparation; Referring to U.S. Pat 5,833,948, the document intactly is incorporated herein by reference.
Can give the combination of pharmaceutical composition.In addition, can be with compositions and other therapeutic agent administering drug combinations.
Dosage continued successfully to treat in 14 days cat's flu, cat leukemia, cat autoimmune malfunction, cat flea and stung dermatitis, cat hyperthyroidism, feline viral infection, cat ulcer, cat bacterial infection, dog flea-bite dermatitis, dog hypercortisolism, malignant tumor, dog autoimmune malfunction, dog disease poison and bacterial infection the 141mg/ of any preparation in the 5th hurdle in table 2,3 or 4 weighs oneself every day.These treatment major parts have caused curing completely.The application of transfer factor in these preparations of expection encapsulation can produce identical or better result.
Make carcinoid size reduce about 60% and make that suffering from the symptom that above-mentioned disease and syndromic animal show has reduced about 90% to the preparation of suffering from dietetic product in all tables 2 that carcinoid animal comprises preferred dose.The application of transfer factor in these preparations of expection encapsulation can produce identical or better result.
Giving in those tables in the 3rd hurdle all dietetic products in the table 2 of low dosage makes the size of tumor reduce about 7%-100% and makes that suffering from the symptom that those diseases or syndromic animal show has reduced 30%-100%.The application of transfer factor in these preparations of expection encapsulation can produce identical or better result.
Stress also be used for the treatment of numerous Animal diseases and syndrome by preparation in the table 5, and as previously mentioned, be mainly used in its acute stage.This preparation also is water miscible, can give in the drinking water of animal thus.Give twice about 0.75mg/lb transfer factor and about 1.42mg/lb bacillus acidophilus 10 every day
9The mixture of colony-forming units (CFU) can cause reducing 30% at least because of the clinical symptoms that colt-ill, dust cough, hypothyroidism and lymphopenia produce.Giving same dose to immature cattle also can make sickness rate descend about 30%.The ion salt or the chelate that add twice calcium every day, magnesium, sodium and the potassium of those amount in approximate table 5 the 4th hurdle in the antibacterial of the transfer factor of above-mentioned consumption and lactic acid producing make the clinical symptoms of above-mentioned disease reduce 40%.The citric acid that adds about 0.482mg/lb in above-mentioned preparation makes the symptom of above-mentioned disease reduce about 45%.Further add vitamin A, B
2, B
6, B
12, C and E and thiamine make the symptom of these diseases reduce 50%.Give stress preparation can curing or treat at least and alleviate the cough of autoimmunity dust of dosage shown in table 5 the 4th hurdle once or twice every day, the diarrhoea that causes by viral etiology, abscess, in the colt-ill, rhinorrhea nose in the colt-ill, acute disease toxemia in the pig, the scratches of Malaysia and China, the allergy that causes because of scratches and onchocerciasis, PURRS, BRD, little moor ill, coliform infects, Rhod infects, Clostridium infects, the porcine circovirus in the birds and the symptom of the pneumonia in the cat.Combination of the antibacterial of transfer factor and lactic acid producing or as shown in table 5 should the combination further also can be treated these diseases with the yeast merging, but degree is lower.The application of the transfer factor of expection encapsulation can produce identical or better result.
Once a day or give for twice as shown in table 5 stress also can improve weight increase and the feed efficiency of domestic animal by preparation.Weight increase can improve at least 8%.The combination of the antibacterial of transfer factor and lactic acid producing maybe should be made up as shown in table 5 further the merging with yeast also can improve weight increase, but degree is lower.The application of the transfer factor of expection encapsulation can produce identical or better result.In preferred embodiments, use the hybridization glucosan of the 2gm encapsulation that contains 1gm hybridization glucosan.
Shown the decomposition that is used for the treatment of and cures the performance preparation of the transfer factor of numerous diseases and dietetic product in the table 6, described disease such as arthritis, laminitis, inflammation and malignant tumor.Can also use these diseases of following combined therapy: transfer factor and superoxide dismutase; Transfer factor and glucosamine salt; Transfer factor, glucosamine salt and superoxide dismutase; Transfer factor, glucosamine salt, superoxide dismutase and glycine; Transfer factor, glucosamine salt, superoxide dismutase, glycine and dimethylsulfone; Transfer factor, glucosamine salt, superoxide dismutase, glycine, dimethylsulfone and octocosonol; Or transfer factor, glucosamine salt, superoxide dismutase, glycine, dimethylsulfone, octocosonol and Montmorillonitum.
Table 7 has shown the preparation that contains transfer factor and hybridization and non--hybridization glucosan.
Any above-mentioned preparation can be mixed the prescription of encapsulation.
Table 1
The Montmorillonitum composition
Every ounce of average nutrient inventory
(1 soupspoon=～0.36oz.)
(mg)
Silicon 6933 tungsten 0.218
Aluminum Silicon stone (Aluminum Silica) 2505 vanadium 0.215
Sodium chloride 1320 rutheniums 0.210
Potassium 1293 Baron 0.189
Protein 1116 bromines 0.140
Calcium 1104 cobalts 0.129
Sulfur 431 selenium 0.110
Ferrum 431 Syprosium 0.107
Magnesium 224 fluorine 0.102
Chlorine 164 scandiums 0.0997
Titanium 61.9 samariums 0.0943
Carbon 48.2 nobeliums 0.0754
Sodium 37.2 bronze medals 0.0593
Barium 10.5 praseodymiums 0.0539
Phosphate 8.62 erbiums 0.0539
Strontium 6.46 hafniums 0.0539
Caesium 4.93 ytterbiums 0.0377
Manganese 4.04 lithiums 0.0377
Thorium 2.69 yttriums 0.0323
Uranium 2.69 holmiums 0.0296
Arsenic 1.97 cadmiums 0.0296
Chromium 1.89 palladiums 0.0189
Molybdenum 1.64 terbiums 0.0161
Nickel 1.62 thuliums 0.0161
Iodine 1.28 gold medals 0.0161
Plumbous 1.17 tantalums 0.0135
Cerium 1.08 iridium 0.0135
Rubidium 0.983 lutecium 0.0108
Antimony 0.781 europium 0.0108
Gallium 0.673 rhodium 0.0108
Germanium 0.673 stannum 0.0108
Neodymium 0.539 silver medal 0.00808
Zinc 0.539 indium 0.00808
Lanthanum 0.486 oxygen 0.00539
Bismuth 0.385 hydrargyrum 0.00269
Zirconium 0.269 tellurium 0.00269
Rhenium 0.269 beryllium 0.00269
Thallium 0.269
Table 2
The premix preparation
(pressing except as otherwise noted, the amount of mg/lb weighing machine)
| Composition | High | Low | Preferably | Dosage: mg/5oz. prescription |
| 1-arginine * Lacto yeast (4.9% admixture) montmorillonite Semen Brassicae Campestris oil (14.5% mixture) safflower oil (14.5% mixture) linseed oil (55% alpha linolenic acid) (1.0% mixture) phosphorus (sodium dihydrogen phosphate) 12% calcium carbonate 8.5% (38% calcium) dimethyl sulfone transfer factor vitamin C (ascorbic acid) D-biotin (biotin 2%) vitamin D3Vitamin B 12Folic acid Niacinimide pantothenic acid (d-calcium pantothenate) 91.6% vitamin B 6(Hcl pyridine) 82.3%) vitamin A (Palimitate-A) 650M IU/g feed grade vitamin B 2Thiamines (single nitric acid salt) 83% vitamin E vitamin K cobalt (protein salt) 5% bronze medal (protein salt) 10% iodine (KI) 98% iron (protein salt) 15% magnesium (oxide) 58% manganese (protein salt) 15% molybdenum (sodium molybdate dihydrate) 39% selenium (sodium selenite) 44.8% zinc (protein salt), 15% 1-lysine (HCl) d, tocopherol Choline Chloride Sipernat 50 (silica) Lodex-5 (maltodextrin) soy meal (17.5% mixture) the sweet whey BF70 spices powdered glucose that the 1-methionine mixes | 0.5 69.51 1gm/lb 1.5gm/lb 1.5gm/lb 1.5gm/lb 15.750gm 13.68gm 20 50.00 21.62 9.73 29.16IU 0.092 1 12 0.324 1.158 600IU 0.0554 3.09 72.9IU 1 0.00043 0.56 0.005 3.31 10 1.65 0.05 0.00162 50 8.41 11.03 | 0.005 0.6951 0.24118 2.05 2.05 2.05 0.0525 0.0485 0.02 0.05 0.2162 0.000973 0.7298IU 0.000092 0.001006 0.012157 0.0108 0.001158 4.02IU 0.002776 0.00308 0.0729IU 0.0007 0.000043 0.0112 0.000053 0.0331 0.04 0.04 0.001 0.000081 0.04987 0.0841 0.1103 | 0.05 6.91 2.4118 20.571 20.57 20.571 5.08 4.88 2 0.75 2.162 0.00973 7.298IU 0.00092 0.01006 0.12157 0.108 0.01158 40.212IU 0.02776 0.0308 0.729IU 0.007 0.00043 0.112 0.00053 0.331 0.4 0.4 0.01 0.00081 0.4987 0.841 1.103 | 50.00 6951.88 2411.88 20571.88 20571.88 1418.75 5080.00 4880.00 2000.00 750.00 2162.50 10.00 7298.38IU 0.92 10.06 121.57 108.00 11.58 40232.50IU 27.76 30.80 729.42IU 7.00 0.43 112.00 0.53 331.16 400.00 332.10 10.00 1.00 498.72 841.57 1103.86 300.00 2434.00 12768.75 7519.38 24828.13 996.00 146.00 750.00 |
(*) antibacterial of lactic acid producing to account for 2/3rds and yeast of this composition be 1/3rd; The antibacterial of lactic acid producing is 500,000,000 CFU/gm, yeast (for example " saccharomyces ") 250,000,000 CFU/gm
Table 3
Dog premix preparation
(pressing except as otherwise noted, the amount of mg/lb weighing machine)
| Composition | High | Low | Preferably | Dosage: mg/oz prescription |
| 1-arginine * Lacto yeast (4.9% admixture) montmorillonite Semen Brassicae Campestris oil (14.5% mixture) safflower oil (14.5% mixture) linseed oil (55% alpha linolenic acid) (1.0% mixture) phosphorus (sodium dihydrogen phosphate) 12% calcium carbonate 8.5% (38% calcium) dimethyl sulfone transfer factor vitamin C (ascorbic acid) D-biotin (biotin 2%) vitamin D3Vitamin B 12Folic acid Niacinimide pantothenic acid (d-calcium pantothenate) 91.6% vitamin B 6(Hcl pyridine) 82.3%) vitamin A (Palimitate-A) 650M IU/g feed grade vitamin B 2Thiamines (single nitric acid salt) 83% vitamin E vitamin K cobalt (protein salt) 5% bronze medal (protein salt) 10% iodine (KI) 98% iron (protein salt) 15% magnesium (oxide) 58% manganese (protein salt) 15% molybdenum (sodium molybdate dihydrate) 39% selenium (sodium selenite) 44.8% zinc (protein salt), 15% 1-lysine (HCl) d, tocopherol Choline Chloride Sipernat 50 (silica) Lodex-5 (maltodextrin) peanut oil soy meal (17.5% mixture) the peanut powder sweet whey BF70 spices powdered glucose that the 1-methionine mixes | 0.5 69.51 1gm/lb 1.5gm/lb 1.5gm/lb 1.5gm/lb 15.750gm 13.68gm 20 50.00 21.62 9.73 29.16IU 0.092 1 12 0.324 1.158 600IU 0.0554 3.09 72.9IU 1 0.00043 0.56 0.005 3.31 10 1.65 0.05 0.00162 50 8.41 11.03 | 0.005 0.6951 0.24118 2.05 2.05 2.05 0.0525 0.0485 0.02 0.05 0.2162 0.000973 0.7298IU 0.000092 0.001006 0.012157 0.0108 0.001158 4.02IU 0.002776 0.00308 0.0729IU 0.0007 0.000043 0.0112 0.000053 0.0331 0.04 0.04 0.001 0.000081 0.04987 0.0841 0.1103 | 0.05 6.91 2.4118 20.571 20.57 20.571 5.08 4.88 2 2.50 2.162 0.00973 7.298IU 0.00092 0.01006 0.12157 0.108 0.01158 40.212IU 0.02776 0.0308 0.729IU 0.007 0.00043 0.112 0.00053 0.331 0.4 0.4 0.01 0.00081 0.4987 0.841 1.103 | 10.00 1390.38 482.20 3887.00 3887.00 240.00 1010.00 977.00 400.00 500.00 432.50 2.00 1459.68IU 0.18 2.16 24.31 21.60 2.32 8046.50IU 5.55 0.16 145.88IU 1.40 0.086 22.40 0.106 66.23 80.00 66.42 2.00 0.20 99.74 176.91 220.77 60.00 486.80 2553.35 1508.87 496.56 4965.02 4965.02 400.00 29.20 500.00 |
(*) antibacterial of lactic acid producing 2/3rds and the yeast that account for this composition accounts for 1/3rd; The antibacterial of lactic acid producing is 500,000,000 CFU/gm, yeast (for example " saccharomyces ") 250,000,000 CFU/gm
Table 4
Cat premix preparation
(pressing except as otherwise noted, the amount of mg/lb weighing machine)
| Composition | High | Low | Preferably | Dosage: mg/2.2gm prescription |
| 1-arginine * Lacto yeast (4.9% admixture) montmorillonite Semen Brassicae Campestris oil (14.5% mixture) safflower oil (14.5% mixture) linseed oil (55% alpha linolenic acid) (1.0% mixture) phosphorus (sodium dihydrogen phosphate) 12% calcium carbonate 8.5% (38% calcium) dimethyl sulfone transfer factor vitamin C (ascorbic acid) D-biotin (biotin 2%) vitamin D3Vitamin B 12Folic acid Niacinimide pantothenic acid (d-calcium pantothenate) 91.6% vitamin B 6(pyrrole is decided Hcl) 82.3%) vitamin A (Palimitate-A) 650M IU/g feed grade vitamin B 2Thiamines (single nitric acid salt) 83% vitamin E vitamin K cobalt (protein salt) 5% bronze medal (protein salt) 10% iodine (KI) 98% iron (protein salt) 15% magnesium (oxide) 58% manganese (protein salt) 15% molybdenum (sodium molybdate dihydrate) 39% selenium (sodium selenite) 44.8% zinc (protein salt), 15% 1-lysine (HCl) d, tocopherol Choline Chloride Sipernat 50 (silica) Lodex-5 (maltodextrin) the sweet whey BF70 spices powdered glucose HCl aminoglucose Pernaconniculus-chondroitin that the 1-methionine mixes | 0.5 69.51 1gm/lb 1.5gm/lb 1.5gm/lb 1.5gm/lb 15.750gm 13.68gm 20 50.00 21.62 9.73 29.16IU 0.092 1 12 0.324 1.158 600IU 0.0554 3.09 72.9IU 1 0.00043 0.56 0.005 3.31 10 1.65 0.05 0.00162 50 8.41 11.03 | 0.005 0.6951 0.24118 2.05 2.05 2.05 0.0525 0.0485 0.02 0.05 0.2162 0.000973 0.7298IU 0.000092 0.001006 0.012157 0.0108 0.001158 4.02IU 0.002776 0.00308 0.0729IU 0.0007 0.000043 0.0112 0.000053 0.0331 0.04 0.04 0.001 0.000081 0.04987 0.0841 0.1103 | 0.05 6.91 2.4118 20.571 20.57 20.571 5.08 4.88 2 16.00 2.162 0.00973 7.298IU 0.00092 0.01006 0.12157 0.108 0.01158 40.212IU 0.02776 0.0308 0.729IU 0.007 0.00043 0.112 0.00053 0.331 0.4 0.4 0.01 0.00081 0.4987 0.841 1.103 | 0.78 108.42 37.00 323.25 323.25 22.13 78.70 75.69 31.20 250.00 33.73 0.156 113.90IU 0.014 0.168 1.90 1.68 0.18 627.60IU 0.43 0.48 11.38IU 0.11 0.006 1.75 0.008 5.17 6.24 5.18 0.156 0.156 7.78 13.80 17.22 4.68 38.0 199.06 117.30 155.37 2.28 250.00 100.00 200.00 |
(*) antibacterial of lactic acid producing 2/3rds and the yeast that account for this composition accounts for 1/3rd; The antibacterial of lactic acid producing is 500,000,000 CFU/gm, yeast (for example " saccharomyces ") 250,000,000 CFU/gm
Table 5
Stress preparation
(pressing except as otherwise noted, the amount of mg/lb weighing machine)
| Composition | High | Low | Preferably | Dosage: mg/ ounce prescription |
| Calcium pantothenate vitamin C (ascorbic acid) vitamin B 12The vitamin A vitamin B 2Thiamines vitamin E magnesium sulfate * lactobacillus acidophilus sodium chloride dipotassium hydrogen phosphate citric acid yeast (hydrolysis) glycine potassium chloride vitamin D3Glucose artificial perfume transfer factor Sipernat (silicon dioxide) | 1.80 20.00 13.00 600.00IU 1.20 16.00 72.9IU 10.00 10.00 166.00 116.00 31.00 180.00 0.142 18.00 29.00 40.00 0.028 50.00 | 0.09 0.056 0.13 0.10IU 0.065 0.0308 0.729IU 0.113 0.467 0.236 5.85 1.59 0.1957 0.0142 0.93 0.729 2.00 0.0028 0.05 | 0.028 0.017 0.198 0.014 0.018 0.017 0.012 0.113 1.418 2.368 1.773 0.482 0.283 0.142 0.283 0.002 21.38 28.548 0.75 0.05 | 28.00 17.00 198.59 14.00 18.00 17.00 12.48 113.00 1418.00 2368.00 1773.00 482.00 283.00 141.80 283.00 1.56 21375.00 28.30 750.00 56.70 |
(*) 10
9Colony-forming units (CFU)/gm
Table 6
The performance preparation
(pressing except as otherwise noted, the amount of mg/lb weighing machine)
| Composition | High * | Low * | Meansigma methods * | Dosage: mg/oz. prescription |
| The transfer factor of superoxide dismutase glucosamine salt 1(horse, cattle) transfer factor 1(goat) transfer factor 1(dog, cat) Pernaconniculus-chondroitin (mucopolysaccharide) boswellic acids two-methylglycine dimethyl sulfone Octocosonol montmorillonite | 60.0 65.0 15.0 10.0 50.0 16.5 30 27.0 27.0 2.0 30.0 | 0.6 0.65 0.15 0.10 0.5 0.165 0.3 0.27 0.27 0.004 0.3 | 6.0 6.5 1.5 1.0 5.0 1.65 3.0 2.7 2.7 0.04 3.0 | 6000.0 6500.0 1500.0 3000.0 14000.0 1650.0 3000.0 2700.0 2700.0 400.0 3000.0 |
* this tittle is for body weight is about 450-1, and 000 pound livestock animals, body weight are about 150 pounds goat and body weight for about 15 pounds Canis familiaris L. of about 8-and cat calculating.
1The amount of transfer factor can change according to different plant species, but the amount of other composition keeps identical to each species.
Table 7
Domestic animal stress the cud diversion agent
(pressing except as otherwise noted, the amount of mg/lb weighing machine)
| Composition | Dosage: mg/oz. (except as otherwise noted) prescription |
| Through stable 1The glucan of the hybridization of transfer factor (mammal source) transfer factor (birds source) cupreol (90% phytosterol) phytic acid Olive leaf P.E aloe extract powder (200: 1) and non--hybridization is (from the Cordyceps sinensis of hybridization, Agaricus blazeii, Miatake, Shitake, Coriolis, Inonotus, Obliquus and Poriscocos mushrooms) vitamin C is non--stable vitamin A cholecalciferol vitamin E vitamin B1 vitamin B2 cobalamin dipotassium hydrogen phosphate potassium chloride magnesium sulfate calcium pantothenate ascorbic acid lactic acid bacteria yeast (Saccharomyces cerevisiae) zinc albuminate | 3500.0 1000.0 300.0 350.0 35.0 17.0 4000.0 2000.0 4434IU/oz 1140IU/oz 500IU/oz 12.77 12.77 1.5 1.5g/oz 207 83 23 23 2.5×10 6CFU/oz 15.0×10 6CFU/oz 10 |
* this tittle is for body weight is about 450-1, and 000 pound livestock animals, body weight are about 150 pounds goat and body weight for about 15 pounds Canis familiaris L. of about 8-and cat calculating.
1In the preparation of 50% soybean oil and 50% active component, comprise through stable active component.
The following example is used for more completely describing the mode of using foregoing invention and has enumerated to implementing the desired optimal mode of various aspects of the present invention.Should understand these embodiment and never be used to limit true scope of the present invention, but be provided for task of explanation.All patents, patent application, public publication and list of references with this paper citation intactly is incorporated herein by reference especially.
The I group
240 hybrid heifer are divided at random three groups of each 80 calf.Weigh to them respectively and their accept by the bovine viral diarrhea virus (BVD) of infectious bovine rhinotrachetis (IBR) virus, deactivation, attenuation-bovine respiratory syncytial virus (BRSV) of living and the parainfluenza-3 (PI3) of deactivation is viral, combined attenuated live-virus vaccine that the polyvalent vaccine toxoid of 7 clostridium kinds is formed; Dormectin dewormer (Ivomec); With the Progesterone implant.In processing back 10 days, give booster dose their initial same attenuated live vaccines of accepting to calf.80 calves of one group average 440.1 pounds when handling by dosage syringe accept 1 ounce of dosage be dissolved in 1 ounce of water as table 5 the 5th hurdle in listed stress preparation.After this, after processing to they be blended in feedstuff (total mix quantitatively-TMR) in 1 ounce of every day stress preparation lasting 4 days of dosage.80 calves that second group of average out to is 440 pounds are at the initially treated 1.5ml/cwt tilmicosin (Micotil) of accepting simultaneously.80 calves that the 3rd group of average out to is 449.9 pounds are as matched group.After processing these groups were observed 26 days, weigh to every calf once more and calculate feed efficiency jointly to every group this moment.
The II group
200 hybrid original seed heifer are divided at random four groups of each 50 calf.Handle them according to the mode identical with original seed in the I group.50 calves of one group average 441 pounds in its TMR, accept every day 1 ounce as listed in table 4 the 5th hurdle stress preparation, continue 5 days.50 calves that second group of average out to is 433 pounds are accepted 1/2 ounce identical in its TMR stress preparation, continues 5 days.50 calves that the 3rd group of average out to is 47 pounds are at the initially treated metaphylactic 1.5ml/cwt tilmicosin/cwt that accepts simultaneously.50 calves that the 4th group of average out to is 432 pounds are as matched group.Every heifer in all four groups is at the back attenuated live virus combination-vaccine of accepting IBR, PI3, BVD and the BSV of booster dose in 10 days of initial processing.After processing each group was observed 26 days, weigh to every calf once more and calculate feed efficiency jointly to every group this moment.
Weight increase is carried out unidirectional variance statistical analysis.Using α=0.05 to carry out the F-check as the error of first kind rate separates with the LSD meansigma methods.Software is SAS (1999), program GLM.
The statistical analysis of used BRD sickness rate: use the chi-square analysis of Fisher ' s Precision Test, have 0.05 or 0.05 following probability and be interpreted as explaining that sickness rate difference has significance between each group.
Listed the result in the table 8 hereinafter and 9.
With regard to I group, being used in 1 ounce of aqueous solution 1 ounce by dosage syringe on the same day of handling stress preparation and after processing 1 ounce stress preparation/sky be joined among the TMR and do not have ill involving (pull) (the ill calf of promptly treating) in lasting 80 heifer treating in 4 days.In from matched group, have 17 ill involve with 4 because of BRD involves again, and in from the tilmicosin group, have 12 ill involve with 1 involve again.
Heifer had in 26 days test time limits in I group average every day, weight increase was 3.63 pounds, had significance,statistical when other two groups are compared.Average weight every day of tilmicosin and matched group increases (ADG) and is respectively 2.96 and 3.08 pounds.Stress preparation, the feed efficiency of tilmicosin and matched group is respectively 6.73,6.94 and 6.66.
Average every day of the weight increase of 1 ounce of heifer in stress the formulation dosage group is 3.2 pounds in II group, those are 3.05 pounds at average every day of the weight increase that 0.5 ounce of heifer in stress the formulation dosage group has, and average weight increase every day that tilmicosin and matched group have is respectively 2.88 and 2.92 pounds.1 ounce stress preparation feed efficiency be 5.31, and double ounce stress preparation, the value of tilmicosin and matched group is respectively 6.09,6.10 and 5.99.
Accept to begin to continue from the same day of handling 5 days join total mixing quantitatively 1 ounce stress preparation/sky the groups of 50 heifer in have that 11 of carrying out the BRD treatment are ill to be involved and involve, and accept among the TMR to exist in the group that 1/2 ounce of TF continues 5 days 13 of carrying out that BRD treats ill involve with 4 involve again.In 30 days test time limit process, in from the tilmicosin group, exist 5 ill involve with 2 involve again.Exist in the matched group heifer 11 BRD ill involve with 2 involve again.
When the ill difference that involves ratio compares between each group in the I group, stress show the significance protection that provides BRD in the test time limit process at 26 days by preparation.Stress preparation have also increased average every day of weight increase significantly.
In II group, the heifer in two groups has obtained better weight increase than other heifer in two groups.Yet, in II group, the protection of BRD is seemed to be lower than tilmicosin.When the do time spent of TF between I group relatively and the II group to BRD, it is inconsistent that the result seems, up to recognize the heifer of II in organizing in processing procedure not by dosage syringe accept initial dose stress preparation.This evidence has been proved effectively and has been given initial dose by dosage syringe or capsule and depend on not exclusively to guarantee each experimenter to accept complete at least initial dose that accept by TMR stress preparation.Two involve in stress the preparation group heifer treated may first key stress day the time the intact part and accepting thus of edible TMR be enough to the enough of stimulating immune system stress preparation.
In the time will accepting heifer that complete ounce stress preparation every day and compare, on the performance of heifer, there is not significant difference with the group of accepting half ounce every day.Very possible is if give two kinds of dosage by dosage syringe or capsule at first, so difference even may be littler.
This body weight value that should notice that in II group the body weight value that stress the preparation group increases surpasses other group and increases surpassed be enough to compensate stress the preparation group in the cost of treatment BRD.
Unpretreated high-risk cattle such as the heifer in these researchs in, with stress the direct stimulating immune system of preparation and vaccine administration seem to have improved really immunity level to BRD.Stress preparation show and reduced the demand of antibiotic therapy and or strengthened the effectiveness of antibiotherapy.
Table 8
The result of I group
Every day, 1oz. stress 1 day decoction being taken at a draught of preparation-Di, 4 days subsequently flush coats
| The treatment group | The heifer number | ADG | Kg(lbs) | Pull | Pull again | Feedstuff usefulness | Ill pull |
| Stress preparation (1oz/ days) tilmicosin (Micotil 1.5ml/cwt) matched group | 80 80 80 | 3.63 2.96 3.08 | 200.0 (440.1) 200.0 (440.0) 204.5 (449.9) | 0 12 17 | 0 1 4 | 6.73 6.94 6.66 | 1.65 1.35 1.40 |
Table 9
The result of II group
Every day stress preparation-5 flush coat day only
| The treatment group | The heifer number | ADG | Kg(lbs) | Pull | Pull again | Feedstuff usefulness | Ill pull |
| Stress preparation (1oz/ days) stress preparation (1/2oz/ days) Tilmicosin (Micotil 1.5ml/cwt) control group | 50 50 50 50 | 3.20 3.05 2.88 2.92 | 200.5 (441.0) 198.8 (433.0) 203.2 (447.0) 196.4 (432.0) | 11 13 5 11 | 4 4 2 2 | 5.31 6.09 6.10 5.99 | 1.45 1.39 1.31 1.33 |
At Fort Bidwell, there is the long-standing problem of calf dysentery in the cows of California, wherein mortality rate be 63% and sickness rate be 90%.This problem has continued 7 years.Do not produce the treatment that improves and comprise antibiotic tetracycline, mycotil, sulfur and penicillium and other traditional treatment, such as liquid and diarrhea, as Kaopectate.The University ofCalifronia, Davis and the University of Washington can not provide solution.Stress the preparation for treating body weight be about 40 test calves of 100 pounds with 1 ounce every day as shown in table 5 the 5th hurdle, send 2 days with capsule form, and the calf of 60 served as control is not accepted any material and is used for prevention.In the test calf, 1 animal dead because its medicine time is late excessively, does not show any disease symptoms but there is 1 in other test animal.Yet the dysentery ratio of control calves accounts for 90%, with formerly the year before last in ratio identical.After calf breaks out dysentery, use immediately stress preparation for treating they, calf takes a turn for the better.At present with 1 ounce as table 5 the 5th hurdle as shown in stress preparation with the new calf in the capsule form treatment cows, and they show with every day 1 lasting 2 days of capsules with test the identical result of calf.With stress the preparation scheme last 20 calves in the cows of treatment pastured and weight increase 7% and have crust and the figure who is better than testing calf by herding.Existing the contiguous ranchero of similar dysentery problem also to begin test in the calf stress the preparation scheme and obtained similar successful result.
Have 40 ovum donor cows to lose its all calves on the farm of Pennsylvania, and some adult milch cow also show ill.The University of Ohio is diagnosed as milch cow and calf and has bacillus aerogenes capsulatus A type.Initial with several these milch cows of available antibiotic therapy and calf, but not success.The sickness rate of calf be 100% and mortality rate be 80%.Scheme begins, and 1 ounce of each personal every day, the calf that stress the preparation for treating body weight be about the 80-100 pound as shown in table 5 the 5th hurdle began to continue 7 days from their nascents.Do not give antibiotic to these calves.Since this scheme begins to have treated about 30 calves, in cows, do not observe dysentery and no longer include calf death.
Embodiment 4
There are the cows of 130 cow heads and calf to suffer from the chronic dysentery in coliform source at Columbus Nebraska.About 60% calf shows and is encroached on.Use antibiotic and liquid undergoing treatment to produce moderate success, mortality rate is about 10%.Every day is with 1 ounce of stress preparation being about the 80-100 pound separately with body weight and suffering from wherein 10 calves treatments 3 days of this dysentery as shown in table 5 the 5th hurdle then.After 3 days, these 10 calves no longer show dysentery sign in this scheme of use.Yet still there is the dysentery problem in untreated calf.
Embodiment 5
With the premix preparation for treating surpass the benign tumor of 50 examples in cat (as shown in table 4 the 5th hurdle 2.2gm/ every day), Canis familiaris L. (as shown in table 3 the 5th hurdle 28.37gm/ every day) and horse and the cattle (5oz./every day as shown in table 2 the 5th hurdle).The scope of these tumors is (pappilomas) from optimum sarcoid to papillary tumor.On the whole, tumor has reduced 40%-80% and even complete obiteration in some case.In accepting the Canis familiaris L. of premix preparation as shown in table 3 the 5th hurdle of 28.37gm/ every day and accepting in the cat of the premix preparation as shown in table 4 the 5th hurdle of 2.2gm/ every day, malignant tumor is reduced such as oral cavity squamous cell carcinoma.
Embodiment 6
Body weight is that 100 cattle of 450 pounds arrive feedlot and proper for to wean from milch cow from barton through 2 hours transported on trucks.Micotil of vaccination by routine and Worming and injection handles in the vaccinated cattle 50 and as matched group.Give other 50 cattle vaccinations, Worming and and give the solution of 1 ounce the antibacterial that contains 1500mg transfer factor and 1418mg lactic acid producing as shown in table 5 separately to them.This dosage is respectively tested cattle by orally give continue 4 days again.After 30 days, the body weight of test cattle weighs 10 pounds than the cattle of using Micotil separately on the antibacterial of using transfer factor and lactic acid producing.
Embodiment 7
There is serious bacillus aerogenes capsulatus A type outburst in 100 cow heads that produce calf, the sickness rate that wherein gives the calf of traditional treatment be 80% and mortality rate be 30%.The calf that body weight is about 110 pounds gives 750mg transfer factor and 1418mg bacillus acidophilus (10 separately
9Colony-forming units (CFU)/gm), continuous 2 days, clostridial sickness rate reduced to 20%, and mortality rate reduces to 5%.
Embodiment 8
The about 600 pounds original seed cattle of 500 body weight transports the back at 6 hours trailers, and each enters feedlot and handles (being Worming and vaccination) at once since barton.Give 750mg transfer factor, 283mg yeast and 2368mg lactic acid according to table 5 pairs 250 or every a calf.Handle other calf, give Micotil some, and to another part give Liquarnycin with sulfonamides in case under recommended dose the different product of test.After 40 days, transfer factor, yeast and lactobacillus calf weigh 12 pounds and calf sickness rate in group such as transfer factor than other calf low 30% than other calf.Butcher yield data and show that the cattle of using transfer factor has big ribeye, low major improvement of butchering refuse and high yield.
Embodiment 9
There is bacillus aerogenes capsulatus A type chronic dysentery in 100 cow head groups of small dairy field in the calf of its first batch of birth.Use conventional treatment still losing calf.With remaining calf its birth back every day with the antibacterial of 1300mg transfer factor as shown in table 5 and 1418mg lactic acid producing and the zymic preparation for treating of 283mg 5 days, described product is sneaked into solution and is gavaged every calf.Sickness rate reduced 60% and mortality rate reduced 80%.
Embodiment 10
Present embodiment has compared the transfer factor of orally give cattle and metaphylactic antibiotic (Micotil) treatment calf and to performance and healthy effect that stress finished cattle.
About 600-700 finished cattle (each 400-500lb) is put into fence and clean water and the long shoot Radix Glycyrrhizae of arbitrarily drinking is provided, after this handle.In 24 hours after arrival, to every animal record body weight and rectal temperature.Handle cattle at random by process equipment, and use the ear tag of numbering to remember the only evaluation of row into.Epizoa (Phonectin) and vaccination were to resist common virus (Bovishield 4) and clostridium (Fortress-7) disease in every animal handled.
Each group that the calf of at every turn loading is hanked the 23-28 head with four road branches.Every an animals received 1-ounce oral dose as shown in table 5 not-the cattle transfer factor (giving) of encapsulation as the liquid oral drencs, and the Micotil of remaining animals received 1.5ml/100lb BW.The quantitative flush coat medicine of cattle transfer factor conduct of replenishing 1 ounce/head/sky for the animal of specifying cattle transfer factor group at the 2nd, 3,4 and 5 day.Each group is assigned randomly to the fence of serial number.Used 4-road viral vaccine (Bovishield-4) to give cattle renewed vaccination vaccine and record temperature in the 7th day after initial the processing.
Experimental diet provides about 45% roughage and 55% concentrate.At definite forage volume that provides to each hurdle cattle about 0700 o'clock of every morning.Feed enough amounts so that the feedstuff that does not consume of trace was only arranged in the groove in the 2nd day morning to cattle.Whole every days of sending each fence every day at about 0800 o'clock are quantitative.When excessive, from groove, take out remaining feedstuff to prevent corruption.The feedstuff that give to take out is weighed and is paid attention in the calculating of food consumption subsequently.
Monitor the clinical sign of the respiratory system disease of animal every day, will show respiratory system disease clinical sign, comprise that the cattle of depression, lethargy, anorexia, cough, rapid breathing, nose and/or eye ejection is accredited as the candidate of treatment.Give the clinical score of animal specified scope from 1 to 4.Clinical score is 1 to be used to identify slight respiratory system disease, and clinical score is the moderate diseases of 2 expressions, and scoring is 3 expression severe respiratory system diseases, and clinical score is 4 to represent moribund animals.Shifting out (involving) from fence, to specify clinical score be 1 or greater than 1 animal and make its arrival be used to measure the processing region of body weight and rectal temperature.Have 1 or greater than the animals received antibiotherapy of 1 clinical score.
All animals of treatment all accept to be used for the standard scheme of respiratory system disease, comprise the tilmicosin (Micotil) of subcutaneous injection 10mg/kg dosage.Write down rectal temperature and after treatment, make cattle turn back to its primary fence.If necessary, repetitive therapy after 48 hours.In whole experiment, gather the information that relates to sickness rate, mortality rate, weight increase rate and feedstuff picked-up.
When during accepting, finishing, weigh to cattle respectively and the aliquot that keeps 10-ml blood is used for the recovery of blood plasma.Merge to receive fence so that go in two pastures each from the cattle equal distribution of each treatment.Transport cattle then so that on native pasture, carry out herding of summer.When finishing the grazing season, cattle and transporting together from the pasture so that last processing.Cattle is distributed in the fence of 4 feedlots, wherein will integrates with single feedlot fence (about 150-180 head) from the cattle of 6 fences.
To be listed in the table 10 from this result of experiment.As can be observed, these animals of accepting the transfer factor treatment have the antibiotic therapy that is significantly higher than the animal of using the Micotil treatment and involve rate, be 73% to 48% promptly for treating first, and is 32% to 14%, and be 17% to 50% for treating for the third time for secondary treatment.
These results show that transfer factor is in that to be used for the treatment of stress cows the time role good not as tilmicosin.
Table 10
| Project | Tilmicosin | Transfer factor |
| The initial body weight of number, the initial rectal temperature of lb, 7-days body weight of deg F, lb 7-days rectal temperature, the picked-up of deg F dry, lb treatment for the first time in last 7 days last 21 days, the % that amounts to treats once more, the % that amounts to treats for the third time, the % death that amounts to, the % of total | 333 492.1 102.5 502.2 102.4 12.8 9.8 48.05 14.11 4.50 0.60 | 332 495.6 102.6 506.3 102.3 12.1 9.6 73.49 31.93 17.47 0.30 |
Embodiment 11
External protein degradation.With rumen fluid separately (matched group), carry out external incubation with casein or with TF.The cud inclusions is available from the Jersey beef cattle of 2 cud intubate, its meals of feeding contain the 76% mineral vitamin premix (DM basis) of steaming cornflakes, 10% alfalfa hay, 3% Semen sojae atricolor powder, 1.2% urea, 5% cane molasses and 4.8%, for arbitrarily picked-up.Remove the bonded organism of any granule by the whole cud inclusions of two-layer cheese cloth coarse filtration and by 4 trials of solid residue washing that McDougall ' the s buffer with preparation will be retained on the cheese cloth, the cumulative volume of use therein buffer equates with the initial volume of coarse filtration rumen fluid.Filter the rumen fluid of coarse filtration with the buffering solution mixture and with they merging by eight layers of cheese cloth then.
Maltose solution, 25mL60mM Hydrazinium sulfate solution and the 25mL that the rumen fluid, 450mL that final inoculum contains (every liter) 450mL coarse filtration contains 100mg/mL maltose from the solid buffer extract of washing, 234mg 2 mercapto ethanol, 50L contains the chloromycetin solution of 1.80mg/mL chloromycetin.Adding Hydrazinium sulfate and chloromycetin is in order to attempt to suppress microorganism panning and NH
3Metabolism with AA.
Will from casein or stress preparation (according to Kjeldahl N
16The predetermined casein of analysis and N concentration that stress preparation) 40mgN be weighed into 500mL Aoron mayer flask and add 100mL McDougall ' s buffer.The flask incubation 1 hour that will contain independent buffer (matched group), buffer+casein or buffer+stress preparation then in 39 ℃ of following temperature-controlled indoor.Use 12 flasks altogether, every kind of processing is duplicated four parts.
By in each flask, adding the 200mL inoculum, fill CO simultaneously
2And start external incubation.Incubation carried out 4 hour time limit and after adding inoculum (0 hour), collect the 1-mL sample immediately and after this collecting once every 30 minutes.In when sampling, the 1-mL sample put into the disposable microcentrifuge tube that contains the refrigerative 25%w/v trifluoroacetic acid of 0.25mL and be stored under-20 ℃ analysis until subsequently.
When analyzing, at room temperature melt sample and then with 21, centrifugal 15 minutes of 000xg and according to Broderick and Kang
17Described, use Technicon III AutoAnalyzer
fAnalyze the NH in the gained supernatant
3With total amino acids concentration.
The calculating of protein degradation rate.Although carried out external incubation, NH in the process at 4 hours
31.5 hours processes, after this NH have only been increased with total amino acids concentration
3Begin to descend prompting NH with total AA concentration
3With total amino acids by microorganism panning.Therefore, in calculating the process of external protein degradation rate, only use time point between 0-1.5 hour.Use following formula to calculate the external protein degradation at each time point place: protein degradation percentage ratio=blank correction value ([NH
3-N])+([total amino acids-N])/join mg N in the flask.Use following formula to calculate the not degrade proteins percentage ratio at each time point place: 100-is degrade proteins percentage ratio not.
Statistical analysis.Use makes not the natural logrithm of degrade proteins percentage ratio that protein degradation rate is determined in regressive regression analysis of time.Gained slope representative in mark/hour protein degradation rate.Use ANOVA
gAnalyze the slope of representing protein degradation rate, wherein flask is made up of protein source as experimental unit and model effect.
Embodiment 12
The cattle feedlot operation of 3,800 finished cattles of tool participates in using the research of the compositions that describes in detail in the table 7.Being used for the most typical practice of this industry is from barton or sells the storehouse and buy finished cattle and then cattle is transported to feedlot.When arriving, the general body weight of animal is 350-550lbs.Cattle is treated, fed and finally reach listing weight.The feedlot that participates in this research used following therapeutic scheme in several years: give Micotil with 1.5cc/cwt; TSV-2 (intranasal IBR-PI-3); Triangle 4 (IBR-PI-3, BVD, BRSV, haemolysis pasteurella (Pasturella hemolyticum) and Haemophilus somnus (Haemophilussomis)); Ivermectin (dashing agent); The ratio of 80mg gives chlortetracycline in the mixing forage that comprises micro-inorganic salt of chopping with every day, continues 21-days.At preceding 1 year of this research, such scheme caused 15 animal deads (3.9%), 1140 animal morbidities (30%), and 200 hairs are given birth to chronic lung disease (consumptive) (5.3%).The scheme of the feedlot that participates in has produced with similar to the national meansigma methods of 3,800 cattle or be better than the statistics value of this numerical value, and the mortality rate of described national meansigma methods is that 247 (6.4%) and sickness rate are 25%-35%.
In this research process, use the compositions that describes in detail in the table 7 to replenish the standard scheme that participates in feedlot.Scheme additional comprises and is included in three successive treatments the 1st day single oral separately and gives 1oz. capsule, the continuous subsequently preparation that gave the 1oz. flush coat in 2 days.
This result of study reflects, by add the compositions that describes in detail in the table 7 in previous scheme, significantly with singularly than improving the previous year and national meansigma methods.Especially, mortality rate reduces by 90% to 15 (0.39%), and sickness rate reduces by 68% to 342 (9%), and waiting a moment property pneumonopathy reduces by 84% to 32 (0.84%).
Except that mortality rate that improves and sickness rate result, this research reflects that also the compositions that describes in detail makes weight increase significantly improve in previous scheme interpolation table 7.In the therapeutic scheme formerly, average weight increases to 45 pounds in the pro-30 days.In the scheme of replenishing, the average weight in the pro-30 days increases to 80 pounds.
Embodiment 13
Having represented the single maximum finance to dairy industry for the lasting and ongoing struggle of keeping acceptable Bulk Tank somatic cell counting (BTSCC) one of consumes.The individual cost of every cattle treatment may surpass $250.Recent studies show that 34.5% SSC that has in all milch cows 200,000-229,000 scope.Antibiotic uses to reducing, the pressure that progressively increases of uptrend further shows the seriousness and the reduction of this problem and keeps the increased requirement of the somatic cell counting of minimizing among the appearance of drug-resistant microorganism strain and the recent national BTSCC.The finance of quality bonus form is awarded to the extra importance of SCC control the interpolation.Therefore, study so that determine the compositions that describes in detail in the table 7 whether to be used for effectively reducing BTSCC.
This research comprises 26 milk selecting because of high somatic cell counting.Matched group (13 cow head) has 1,854,811 the initial meansigma methods of SCC.Treatment group (13 cow head) has 2,374,000 the initial meansigma methods of SCC.Milch cow in the matched group is accepted standard scheme in 60-days research time limit process.The milch cow of treatment is accepted the compositions that describes in detail in for three days on end the 1oz. table 7, is 3 days rest period subsequently, amounts to three cycles (amounting to nine treatments).
To disclose the SCC that matched group has be 2,049,636 (increasing by 10.5%) for the SCC of matched group and treatment group test after 26 days, and the SCC that the treatment group has is 957,455 (reducing 59.7%).Therefore, the treatment group has 70.2% improvement, is better than matched group.In addition, the SCC counting when test in 90-days shows that SCC has reduced 26%, has shown the residual effect of described compositions.
Embodiment 14
Buying 64 head heights stress the original seed cattle and give two 1oz. capsules that contain the compositions that describes in detail in the table 7 to 32 (treatment groups) at first, and remaining 32 (matched groups) are kept not treating.Also the treatment group is given the said composition of 1oz. every day, continue 2 days again.Treatment group or matched group are not accepted antibiotic therapy.After 3 weeks, need treatment from 5 calves of treatment group because of morbidity, and have 12 calves to need this class treatment (sickness rate reduces 60% improvement) from matched group.In addition, although 1 calf death is arranged in matched group, no calf death in seminar.
Embodiment 15
7 goats suffer from serious blood-shot eye illness, Chlymidia, other bacterial infection or almost blind separately.All 7 goats are used standard 3 weeks of medication, almost do not have or do not have improvement.Then all ill goats are given the compositions of detailed description in the 1oz. table 7 every day, continue 14 days.2 goats that break out disease stopped progress in about 48 hours, other goat returned in 10 days normally, and eye does not have that boss also reduces in the goat of cicatrization and infection.In this programme, do not use antibiotic.
Embodiment 16
The Cordyceps fungi growth
The ideal culture medium that is used for the growth of Cordyceps solid substrate is as follows :-4 portions of white chinese sorghums of 1 portion of white broomcorn millet (band shell) (band shell), add 0.8%w/w Concha Ostreae powder and 1%w/w vegetable oil (Oleum Arachidis hypogaeae semen or soybean oil).Add entry to equaling 50% total moisture in the aseptic substrate.This maslin was precooked 4-6 hour, after this sterilize, this process trends towards causing the growth response more fast of Cordyceps.On this culture medium, Cordyceps can be grown the long-time time limit, becomes mycelium and expresses secondary metabolite from Cordyceps fully near complete conversion of substrate.The gained Cordyceps is about the pure mycelium of the remaining grain of 3-4% or about 96-98% when growing on this substrate.The helpfulness of this growing method reality is to have won whole presents of metabolite outside the born of the same parents that in complete growth course from start to finish, produce.Owing in this mixture, added the chemical compound of certain initiation growth, so be easy in the presence of no any insecticide material, induce Cordyceps in culture, to produce sporophore.Yet the formation of sporophore on this culture medium can not produce any significance to the analytical chemistry characteristic and change.
Use above-mentioned substrate, the complete chemical characteristic of the Cordyceps of cultivation still can't reach the Cordyceps of wild collection, unless it is grown in very under the specific conditions.Cordyceps produces relative a large amount of free adenosine during growth under normal air oxygen level and room temperature.It also produces a large amount of uridnine and guanosine.If any, only there is very a spot of cordycepin to produce, and in fact do not have the ethoxy adenosine.With regard to the organism that produces these chemical compounds, it need be by not existing oxygen, temperature to descend and the complete unglazed growth of coercing.It is of no use only just to grow under the cold-peace anaerobic condition from beginning, because when Cordyceps is grown under those conditions, its forms has the very yeast sample phorozoon of different chemical characteristic.Must at first under heat and quick condition, grow, lure that then they change into the target medicinal compound with its " summer " metabolite into.In order to obtain these target compounds, follow strict growth protocols.After being seeded on ground/chinese sorghum substrate, make that Cordyceps is grown under 20-22 ℃, under the air oxygen of in the diverging light and sea level 28-30 days.It is indoor then it to be moved into controlled environment, and wherein oxygen is reduced to 50% air oxygen, promptly about 10% oxygen.The airborne remainder of growing is made of nitrogen, carbon monoxide and carbon dioxide.Make temperature reduce to 3 ℃, and get rid of all light.Hold it in about 15-20 week under these conditions.This process causes most of adenosines to change into cordycepin, two deoxidation-adenosine and ethoxy-adenosine.Also produced many other unique ucleosides, final chemical characteristic is mated wild cordyceps fully and is belonged to.
Embodiment 17
Hybridization glucosan preparation
In case determined substrate and growth parameter(s) for optimizing target compound, just determined chemical characteristic difference from the Cordyceps different strains.Owing to exist so many Cordyceps bacterial strain and bacterial strain to have himself unique chemical characteristic separately, so tested the bacterial strain of all acquisitions.Confirm not have in the known bacterial strain a kind of amount that is similar to the active component of in wild Cordyceps, finding that produces.In order to increase the output of target compound quantitatively, carry out the hybrid experiment of Cordyceps bacterial strain; They are hybridized so that obtain more large-tonnage target compound.Carry out various experiments so that obtain different fungal bacterial strains and implement the nuclear fusion of himself.For example, nicotinic acid can be used for generating the hybridization mycelium.This chemical compound is difficult to use and produce insecure result.Attempt several different chemical compounds with after causing this fusion, finding snake venom role the best.
Purification is used for the snake venom [Sigma Scientific, St.Louis, Missouri, USA] of hybrid experiment from the diamondback rattle snake in west (rattle snake (Crotalus atrox)).This snake venom is joined in the agar culture medium, and its addition changes growth, but confirmation can be to described bacterial strain toxigenicity.The amount ranges of this snake venom is at the 10mg-30mg/300ml agar culture medium.This venom is heat-labile and must adds with sterile manner behind medium sterilization.Be used for this hybridization for agar is called the Aloha Medicinals of R7 agar, Inc., Maui, the proprietary agar of Hawaii, it is by beerwort, active carbon, mineral and humus-form from the rich carbonaceous grey residue of coal combustion industrial process.Definite preparation is listed in the table 11.Also can use other agar.
Table 11
Snake venom/R7 agar prescription
| 2.1L | Distilled water |
| 50g | Light beerwort |
| 34g | Agar |
| 10g | Humus |
| 5g | Active carbon |
| 1g | MgSO 4 |
| 10ml | 1%KOH solution |
| As required | Rattle snake (C.atrox) venom |
Give the mycelium of the culture dish inoculation of this R7 agar culture medium from two kinds of different Cordyceps bacterial strains.They are generally two kinds of Cordyceps mutation, and but, we also with the kind of Cordyceps and other Cordyceps, hybridize such as Cordyceps militaris (L.) Link., Cicadae young pilose antler and C.ophioglossoides.These different strains are generally growth toward each other on by co-inoculation to a culture dish time, almost meets up to them, and this moment, their formed inhibition zone band, and none bacterial strain can be grown therein.Finally, a kind of bacterial strain can be better than another kind and on flat board undue growth, but they still keep the difference in the heredity; Two kinds of different cultures are resided on identical culture dish.
Add enough snake venom to agar, two kinds of cultures are grown toward each other, meet and form its mutual inhibition zone band up to them.Yet this inhibitory stage is limited to short-life, and in only about 2 or 3 hours, bacterium colony begins the mycelia bar is transmitted into the inhibition zone band separately.These mycelia bar syntrophism and by its cell wall exchange nuclear matter through venom reduction.They form hybrid strain on this new hybrid strain that obviously is different from parnet strain is in contact with one another a little.In about 4 hours, hybridization finishes and bacterium colony restarts to grow fast toward each other behind the band of initial formation inhibition zone.They become three kinds of bacterium colonies, two kinds of primary colonies and a kind of new hybrid strain.
The part of the hybrid that careful taking-up newly forms from the band of primary inhibition zone when the correct time that bacterium colony begins to merge.Promptly in bacterium colony meets the 3-4 hour process in back at first.Hybrid is changed in the new culture dish that contains general (nothing-snake venom) agar.A kind of method of measuring hybridization is to all three kinds of bacterial strains of the new plating that contains general agar, promptly two kinds primary and suspect for hybrid.If hybridization in fact takes place, they are three kinds of different bacterium colonies now so, and can form mutual three-dimensional inhibition zone band.If hybridization does not take place, the hybrid of Huai Yiing is easy to each other or merges with another kind of primary colony so, thereby confirms that the hybrid of suspecting is easy to one or another kind of fusion in the primary colony, confirms that the hybrid of suspecting not is to be different from original strain in heredity.
In case confirmed hybrid, just tested its growth parameter(s).If vigorous and cold-resistant growth-gen on substrate, occurs, make it grow a certain amount of mycelium so, collect and analyze active component.By retest in this manner, prepared and be easy to the hybrid strain of in the solid substrate culture, growing, it has than the higher usefulness of the bacterial strain of other cultivation arbitrarily and be equal to the first water wild cordyceps at least on rendeing a service and belongs to.This new bacterial strain is Cordyceps (Cordyceps sinensis) Alohaenis.
Embodiment 18
Treatment that stress cattle
In the table 7 listed transfer factor preparation be used to study stress under original seed cattle alive.Calf is given this cud shunting preparation of the consumption in 1 ounce/head/sky, continue 4 days.318 calves are arranged with this transfer factor preparation for treating.180 calves are arranged in matched group colony.Give all calf vaccination and insulations.
Appear in the accompanying drawing 1 from this result of experiment.As can be observed, the sickness rate in the matched group colony be about 15.5%, and the sickness rate in the transfer factor treatment colony is 3.1%.In addition, the mortality rate in the matched group colony is 5.5%, and the mortality rate in the colony of transfer factor treatment is 0%.Weight increase every day of matched group is 1.85 pounds/day, and the daily weight increase that the colony that uses transfer factor to treat has is about 3.05 pounds/day.
Embodiment 19
In another research, with the transfer factor preparation of 1 ounce of table 7 585 calves were treated 3 days and in the time of the 12nd day, are inoculated in the process of vaccine preparation for treating every day with 1 ounce of table 7.The matched group colony of 29 calves does not accept the preparation of table 7.All calves in this research are all accepted vaccine and antibiotic (Micotil or A-1A) and Worming (Ibomec).These calves were cultivated 4-6 days to 45 days, if necessary, dehorned and all bulls castratings.Calculate average daily weight increase based on the body weight that enters and leave at culture farm.
As can be observed in accompanying drawing 2, the sickness rate of matched group accounts for 83%, and the sickness rate in the colony of transfer factor treatment only is 2.6%.Similarly, the mortality rate in the matched group colony is 24.1%, and by comparison, mortality rate is 0% in the colony of use transfer factor treatment.In each case, the death in the matched group colony is the result of cattle respiratory system disease.In addition, the daily weight increase in the matched group is lower than 1 pound/day, and uses those animals of transfer factor treatment to obtain about 3.1 pounds/day weight increase.
Potential cross reactivity
| Human pathogen or disease | General character | The cattle disease substance |
| Diarrhoea clostridial infection (non--lockjaw) the clostridium difficile mycobacterial infections johnei that bacterium traveller disease (Escherichia coli) bloody diarrhea/hemolytic uremia Salmonella infection/typhoid fever salmonella typhi causes because of food or water, the helicobacter pylori (ulcer) of Crohn disease staphylococcus superinfection streptococcal infection endocarditis superinfection streptococcus pyogenes enterococcus hospital/VRE bacterial strain seriousness | It is common common to increase very much jointly very common common increase | Produce the Escherichia coli campylobacter jejuni colon bacillus 0157 of poison: H7 Verotoxic salmonella typhimurium, dublin campylobacter jejuni clostridium (numerous species) Mycobacterium kind be common staphylococcus aureus streptococcus Beta streptococcus streptococcus pyogenes enterococcus (most of Shu Zhong ﹠ VRE) ox/pig combination in the Jersey ox |
| Virus influenza respiratory tract syncytial virus papilloma, Condylomaya virus diarrhea rotavirus cytomegalovirus herpes infection HIV (retrovirus) rhinovirus (common cold) | Jointly very | Influenza virus bovine respiratory syncytial virus bovine papilloma virus bovine viral diarrhoea rotavirus coronavirus ox CMV and IBR bovine rhinotracheitis BIV bovine rhinovirus |
| Yeast, fungus and protozoacide candidiasis cryptosporidiosis giardiasis | Very common jointly | The common calf diarrhoea of Candida exp., C.parvum calf diarrhoea, G.lamblia |
| Other mycoplasma pneumonia, arthritis | Jointly | The Mycoplasma bovis pneumonia |
Potential cross reactivity
| Human pathogen or disease | General character | The birds pathogen |
| The diarrhoea clostridial infection pasteurellosis pneumonia general infection diarrhoea that bacterium traveler's diarrhea (Escherichia coli) bloody diarrhea/hemolytic uremia diarrhoea Salmonella infection causes because of food or water, general infection | Increase very jointly very jointly very very much | Produce the Escherichia coli campylobacter jejuni colon bacillus 0157 of poison: H7 verotoxic 01; 02; 047, other Salmonella kind campylobacter jejuni fusobacterium kind multocida chicken haemophilic bacterium chicken mycoplasmas CPN erysipelothrix porci monocyte Listeria monocytogenes |
| Virus varicella influenza infective bronchitis adult leukemia virus (ATLV-1) pneumonia herpes infection | Very common rare common | Fowl pox influenza virus infectious bronchitis Marek's disease virus paramyxovirus herpes simplex virus |
| The fungus pneumonia, systemic disease diarrhoea, systemic disease diarrhoea, thrush, vaginitis systemic disease systemic disease | Very | Aspergillus kind aspergillus kind Candida albicans Histoplasma capsulatum coccidium |
| Parasite trichomonacide diarrhoea | Very | The Trichomonas Giardia |
Claims (41)
1. method comprises that to animals administer transfer factor preparation, wherein said preparation comprises the transfer factor with hydrophobicity or lipid coating encapsulation.
2. the described method of claim 1, wherein said hydrophobic coatings comprise essential fat and/or vegetable oil.
3. the described method of claim 2, wherein said vegetable oil comprises soybean oil.
4. the described method of claim 1, wherein said preparation further comprises glucosan.
5. the described method of claim 4, wherein said glucosan is the hybridization glucosan.
6. the described method of claim 4, wherein said glucosan is with hydrophobicity or lipid coating encapsulation.
7. the described method of claim 6, wherein said hydrophobic coatings comprise essential fat and/or vegetable oil.
8. the described method of claim 7, wherein said vegetable oil comprises soybean oil.
9. the described method of claim 1, wherein said transfer factor is the transfer factor of targeting.
10. the described method of claim 9, the transfer factor targeting of wherein said targeting is to herpes simplex virus 1, herpes simplex virus 2, helicobacter pylori, Champhobactor or chlamydia.
11. the described method of claim 1 wherein saidly is administered for prevention.
12. the described method of claim 1, the wherein said treatment pathologic situation that is administered for.
13. the described method of claim 12, wherein said pathologic situation are selected from the group that heart disease, inflammatory diseases and angiopathy are formed.
14. the described method of claim 1, the wherein said efficient that increases food conversion that is administered for.
15. compositions comprises the transfer factor with hydrophobicity or lipid coating encapsulation.
16. the described compositions of claim 15, wherein said hydrophobic coatings comprise essential fat or vegetable oil.
17. the described compositions of claim 16, wherein said vegetable oil comprises soybean oil.
18. the described compositions of claim 15 further comprises glucosan.
19. the described compositions of claim 18, wherein said glucosan is the hybridization glucosan.
20. the described compositions of claim 18, wherein said glucosan is with hydrophobicity or lipid coating encapsulation.
21. the described compositions of claim 20, wherein said hydrophobic coatings comprise essential fat and/or vegetable oil.
22. the described compositions of claim 21, wherein said vegetable oil comprises soybean oil.
23. the described compositions of claim 15, wherein said transfer factor are the transfer factor of targeting.
24. the described compositions of claim 22, the transfer factor targeting of wherein said targeting is to herpes simplex virus 1, herpes simplex virus 2, helicobacter pylori, Champhobactor or chlamydia.
25. method comprises the preparation that animals administer is comprised glucosan, wherein said glucosan is with hydrophobicity or lipid coating encapsulation.
26. the described method of claim 25, wherein said glucosan is the hybridization glucosan.
27. the described method of claim 25, wherein said hydrophobic coatings comprise essential fat and/or vegetable oil.
28. the described method of claim 27, wherein said vegetable oil comprises soybean oil.
29. the described method of claim 27, wherein said preparation further comprises transfer factor.
30. the described method of claim 29, wherein said transfer factor is with hydrophobicity or lipid coating encapsulation.
31. the described method of claim 30, the described hydrophobic coatings of wherein said transfer factor comprise essential fat and/or vegetable oil.
32. the described method of claim 28, wherein the described vegetable oil of the described transfer factor of encapsulation comprises soybean oil.
33. compositions comprises the glucosan with hydrophobicity or lipid coating encapsulation.
34. the described compositions of claim 33, wherein said glucosan is the hybridization glucosan.
35. the described compositions of claim 33, wherein said hydrophobic coatings comprise essential fat or vegetable oil.
36. the described compositions of claim 35, wherein said vegetable oil comprises soybean oil.
37. the described compositions of claim 33 further comprises transfer factor.
38. the described compositions of claim 37, wherein said transfer factor is with hydrophobicity or lipid coating encapsulation.
39. the described compositions of claim 38, the described hydrophobic coatings of wherein said transfer factor comprise essential fat or vegetable oil.
40. the described compositions of claim 39, wherein said vegetable oil comprises soybean oil.
41. compositions comprises transfer factor and hybridization glucosan.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US57311304P | 2004-05-20 | 2004-05-20 | |
| US60/573,113 | 2004-05-20 | ||
| US60/649,363 | 2005-02-01 | ||
| US11/106,054 | 2005-04-13 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN1988888A true CN1988888A (en) | 2007-06-27 |
Family
ID=38185389
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 200580022833 Pending CN1988888A (en) | 2004-05-20 | 2005-05-17 | Encapsulated transfer factor compositions and methods of use |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1988888A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101181626B (en) * | 2007-11-29 | 2010-09-22 | 成都利尔药业有限公司 | Transfer factor capsule and preparation method thereof |
-
2005
- 2005-05-17 CN CN 200580022833 patent/CN1988888A/en active Pending
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101181626B (en) * | 2007-11-29 | 2010-09-22 | 成都利尔药业有限公司 | Transfer factor capsule and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Ezema | Probiotics in animal production: A review | |
| US8496923B2 (en) | Probiotic treatment for infectious gastrointestinal diseases | |
| US20090053197A1 (en) | Transfer Factor Compositions and Methods | |
| JP2020508696A (en) | Microbial cells, methods for producing them, and uses thereof | |
| JP4584577B2 (en) | Methods and compositions for the control of coccidium | |
| US20060073197A1 (en) | Encapsulated transfer factor compositions and methods of use | |
| JP2005539070A (en) | Antibacterial compositions and methods for use | |
| TWI359666B (en) | ||
| US20100221316A1 (en) | Encapsulated Transfer Factor Compositions and Methods of Use | |
| AU2019354424A1 (en) | Composition and methods for treating acute diarrhea and enteric infections in animals | |
| Greko | Safety aspects on non-use of antimicrobials as growth promoters | |
| CN116635049A (en) | Antimicrobial compositions and methods of manufacture and products thereof | |
| Arczewska-Włosek et al. | Nutrition as a modulatory factor of the efficacy of live anticoccidial vaccines in broiler chickens | |
| EP3860630B1 (en) | Probiotic bacillus spp. for farm animals | |
| US20130302412A1 (en) | Transfer Factor Compositions | |
| CN1988888A (en) | Encapsulated transfer factor compositions and methods of use | |
| JP2020509743A (en) | Feed additive preparation and its production and use | |
| Heinzl et al. | The Zinc Oxide ban: What led to it, what are the alternatives? | |
| Odede | Use of non-antibiotic growth promoters in chicken broiler production in Kenya | |
| US20130122075A1 (en) | Encapsulated transfer factor compositions and methods of use | |
| Botlhoko | Performance of Clostridium perfringens-challenged broilers inoculated with Effective Microorganisms | |
| El-Diasty et al. | Effectiveness of Dietary Pediococcus on Growth and Some Vital Biochemical Parameters in Calves | |
| Amoah | The effects of Re-3, a Direct-Fed Microbial (DFM) product on the growth performance, blood profile and carcass characteristics of pigs. | |
| Jones | Feed Additives: Assessing the Next Step Towards an Antibiotic-free Commercial Poultry Industry | |
| Heinzl et al. | Necrotic enteritis in poultry |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C12 | Rejection of a patent application after its publication | ||
| RJ01 | Rejection of invention patent application after publication |
Open date: 20070627 |